Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | PI4KA | P42356 | 1/20 | 0.70 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.70 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.70 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.59 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984022 | 1.00 | ADORA2A (0.70) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5459069 | 0.88 | DAPK1 (0.67) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8174343 | 0.85 | HDAC6 (0.70) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6659705 | 0.84 | HDAC6 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5453774 | 0.84 | HDAC6 (0.62) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28781461 | 0.83 | HDAC6 (0.51) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30586358 | 0.83 | ADORA2A (0.68) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| 9-Benzyl-9H-Adenine SCHEMBL104932 | 0.83 | ADORA2A (1.00) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2979897 | 0.83 | ADORA2A (0.68) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4346676 | 0.83 | ADORA2A (0.68) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7330770-A | — | — | None | — | — | JP | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| CN-117430609-B | Purine derivative compound, preparation method and application thereof | 东北农业大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-117430609-A | Purine derivative compound, preparation method and application thereof | 东北农业大学 | 2024-01-23 | — | — | CN | disclosed |
| EP-1615926-A1 | (PURIN-6-YL) AMINO ACID AND PRODUCTION METHOD THEREOF | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (CZ) | 2006-01-18 | — | — | EP | disclosed |
| WO-2006002846-A2 | NEW ANALOGS OF NITROBENZYLTHIOINOSINE | Grünenthal GmbH (DE) | 2006-01-12 | — | — | WO | disclosed |
| CN-1720246-A | (Purin-6-yl) amino acid and production method thereof | USTAV ORGANICKE CHEMIE A BIOCH (CZ) | 2006-01-11 | — | — | CN | disclosed |
| EP-1612210-A1 | New analogs of nitrobenzylthioinosine | Grünenthal GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094426-A1 | (PURIN-6-YL) AMINO ACID AND PRODUCTION METHOD THEREOF | USTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED CESKÉ REPUBLIKY (CZ) | 2004-11-04 | — | — | WO | disclosed |
| EP-1444982-A1 | The use of purine derivatives as selective kinase inhibitors | MERCKLE GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| JP-H07330770-A | PURINE DERIVATIVE AND TREATING AGENT CONTAINING THE DERIVATIVE AS ACTIVE COMPONENT | JAPAN ENERGY CORP | 1995-12-19 | — | — | JP | disclosed |
| WO-1993018035-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
| US-4020073-A | Process for O-acylating thallus salts of 2-pyridone | TAYLOR EDWARD C | 1977-04-26 | — | — | US | disclosed |
| US-3947488-A | O-Acylation using organothallium compounds | TAYLOR EDWARD C | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | ADORA2A 4548/4885PI4KA 409/4885PI4K2B 621/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | ADORA2A 4548/4885PI4KA 409/4885PI4K2B 621/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | ADORA2A 4548/4885PI4KA 409/4885PI4K2B 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.